Synapse Open Synapse
Biology

STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

STAT News · · 1 min read

Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.

Same story elsewhere

Latest from STAT News